Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2

Peiyang Ding,1,2,* Qianyue Jin,1,3,* Xinxin Chen,1 Suzhen Yang,1 Junqing Guo,1 Guangxu Xing,1 Ruiguang Deng,1 Aiping Wang,4 Gaiping Zhang1–4 1Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou 450002, People’s Republic of China...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ding P, Jin Q, Chen X, Yang S, Guo J, Xing G, Deng R, Wang A, Zhang G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Influenza A virus Porcine circovirus type 2 M2e Nanovaccine Virus-like particles Bivalent vaccine Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/3219e79ebead46d5ba70205e6408950a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3219e79ebead46d5ba70205e6408950a
record_format	dspace
spelling	oai:doaj.org-article:3219e79ebead46d5ba70205e6408950a2021-12-02T08:10:46ZNanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 21178-2013https://doaj.org/article/3219e79ebead46d5ba70205e6408950a2019-09-01T00:00:00Zhttps://www.dovepress.com/nanovaccine-confers-dual-protection-against-influenza-a-virus-and-porc-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Peiyang Ding,1,2,* Qianyue Jin,1,3,* Xinxin Chen,1 Suzhen Yang,1 Junqing Guo,1 Guangxu Xing,1 Ruiguang Deng,1 Aiping Wang,4 Gaiping Zhang1–4 1Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou 450002, People’s Republic of China; 2College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, People’s Republic of China; 3School of Life Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of China; 4Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, People’s Republic of China*These authors contributed equally to this workCorrespondence: Aiping WangSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of ChinaTel +86 371 67739345Fax +86 371 63558998Email pingaw@126.com  Gaiping ZhangCollege of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, People’s Republic of ChinaTel +86 371 65723268Fax +86 371 65738179Email zhanggaip@126.comBackground: The influenza A virus (IAV) is known for its high variability and poses a huge threat to the health of humans and animals. Pigs play a central role in the cross-species reassortment of IAV. Ectodomain of matrix protein 2 (M2e) is the most conserved protective antigen in IAV and can be used to develop nanovaccines through nanoparticles displaying to increase its immunogenicity. However, the high immunogenicity of nanoparticles can cause the risk of off-target immune response, and excess unwanted antibodies may interfere with the protective efficacy of M2e-specific antibodies. Therefore, it is necessary to select reasonable nanoparticles to make full use of antibodies against nanoparticles while increasing the level of M2e-specific antibodies. Porcine circovirus type 2 (PCV2) is the most susceptible virus in pigs and can promote IAV infection. It is meaningful to develop a vaccine that can simultaneously control swine influenza virus (SIV) and PCV2.Methods: In the present study, M2e of different copy numbers were inserted into the capsid (Cap) protein of PCV2 and expressed in Escherichia coli to form self-assembled chimeric virus-like particles (VLPs) nanovaccine. BALB/c mice and pigs were immunized with these nanovaccines to explore optimal anti-IAV and anti-PCV2 immunity.Results: Cap is capable of carrying at least 81 amino acid residues (three copies of M2e) at its C-terminal without impairing VLPs formation. Cap-3M2e VLPs induced the highest levels of M2e-specific immune responses, conferring protection against lethal challenge of IAVs from different species and induced specific immune responses consistent with PCV2 commercial vaccines in mice. In addition, Cap-3M2e VLPs induced high levels of M2e-specific antibodies and PCV2-specific neutralizing antibodies in pigs.Conclusion: Cap-3M2e VLP is an economical and promising bivalent nanovaccine, which provides dual protection against IAV and PCV2.Keywords: influenza A virus, porcine circovirus type 2, M2e, nanovaccine, virus-like particles, bivalent vaccineDing PJin QChen XYang SGuo JXing GDeng RWang AZhang GDove Medical PressarticleInfluenza A virusPorcine circovirus type 2M2eNanovaccineVirus-like particlesBivalent vaccineMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 7533-7548 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Influenza A virus Porcine circovirus type 2 M2e Nanovaccine Virus-like particles Bivalent vaccine Medicine (General) R5-920
spellingShingle	Influenza A virus Porcine circovirus type 2 M2e Nanovaccine Virus-like particles Bivalent vaccine Medicine (General) R5-920 Ding P Jin Q Chen X Yang S Guo J Xing G Deng R Wang A Zhang G Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
description	Peiyang Ding,1,2,* Qianyue Jin,1,3,* Xinxin Chen,1 Suzhen Yang,1 Junqing Guo,1 Guangxu Xing,1 Ruiguang Deng,1 Aiping Wang,4 Gaiping Zhang1–4 1Henan Provincial Key Laboratory of Animal Immunology, Henan Academy of Agricultural Sciences, Zhengzhou 450002, People’s Republic of China; 2College of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, People’s Republic of China; 3School of Life Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of China; 4Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou University, Yangzhou 225009, People’s Republic of China*These authors contributed equally to this workCorrespondence: Aiping WangSchool of Life Sciences, Zhengzhou University, Zhengzhou 450001, People’s Republic of ChinaTel +86 371 67739345Fax +86 371 63558998Email pingaw@126.com  Gaiping ZhangCollege of Animal Science and Veterinary Medicine, Henan Agricultural University, Zhengzhou 450002, People’s Republic of ChinaTel +86 371 65723268Fax +86 371 65738179Email zhanggaip@126.comBackground: The influenza A virus (IAV) is known for its high variability and poses a huge threat to the health of humans and animals. Pigs play a central role in the cross-species reassortment of IAV. Ectodomain of matrix protein 2 (M2e) is the most conserved protective antigen in IAV and can be used to develop nanovaccines through nanoparticles displaying to increase its immunogenicity. However, the high immunogenicity of nanoparticles can cause the risk of off-target immune response, and excess unwanted antibodies may interfere with the protective efficacy of M2e-specific antibodies. Therefore, it is necessary to select reasonable nanoparticles to make full use of antibodies against nanoparticles while increasing the level of M2e-specific antibodies. Porcine circovirus type 2 (PCV2) is the most susceptible virus in pigs and can promote IAV infection. It is meaningful to develop a vaccine that can simultaneously control swine influenza virus (SIV) and PCV2.Methods: In the present study, M2e of different copy numbers were inserted into the capsid (Cap) protein of PCV2 and expressed in Escherichia coli to form self-assembled chimeric virus-like particles (VLPs) nanovaccine. BALB/c mice and pigs were immunized with these nanovaccines to explore optimal anti-IAV and anti-PCV2 immunity.Results: Cap is capable of carrying at least 81 amino acid residues (three copies of M2e) at its C-terminal without impairing VLPs formation. Cap-3M2e VLPs induced the highest levels of M2e-specific immune responses, conferring protection against lethal challenge of IAVs from different species and induced specific immune responses consistent with PCV2 commercial vaccines in mice. In addition, Cap-3M2e VLPs induced high levels of M2e-specific antibodies and PCV2-specific neutralizing antibodies in pigs.Conclusion: Cap-3M2e VLP is an economical and promising bivalent nanovaccine, which provides dual protection against IAV and PCV2.Keywords: influenza A virus, porcine circovirus type 2, M2e, nanovaccine, virus-like particles, bivalent vaccine
format	article
author	Ding P Jin Q Chen X Yang S Guo J Xing G Deng R Wang A Zhang G
author_facet	Ding P Jin Q Chen X Yang S Guo J Xing G Deng R Wang A Zhang G
author_sort	Ding P
title	Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
title_short	Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
title_full	Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
title_fullStr	Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
title_full_unstemmed	Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2
title_sort	nanovaccine confers dual protection against influenza a virus and porcine circovirus type 2
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/3219e79ebead46d5ba70205e6408950a
work_keys_str_mv	AT dingp nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT jinq nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT chenx nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT yangs nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT guoj nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT xingg nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT dengr nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT wanga nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2 AT zhangg nanovaccineconfersdualprotectionagainstinfluenzaavirusandporcinecircovirustype2
_version_	1718398594163146752

Nanovaccine Confers Dual Protection Against Influenza A Virus And Porcine Circovirus Type 2

Ejemplares similares